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Cardiovascular disease in populations with obesity is a major concern because 
of it is epidemic proportion. Obesity leads to the development of cardiomyopathy 
directly via inflammatory mediators and indirectly by obesity-induced hyper-
tension, diabetes, and coronary artery diseases. Metabolic disturbances such as 
increased free fatty acid levels, insulin resistance, elevated levels of adipokines, myo-
cardial remodeling, activation of the sympathetic nervous and renin-angiotensin-
aldosterone systems, and small-vessel disease are the most important mechanisms 
in the development of obesity cardiomyopathy. The myocardial changes related with 
obesity are increasingly recognized, and they are independent of classic risk factors 
as hypertension, coronary artery disease, and obstructive sleep apnea. There is a 
wide range of evidence: the association between heart failure and obesity shown 
in epidemiologic studies; the confirmation of the association of adiposity with left 
ventricular dysfunction, independent of hypertension, coronary artery disease, 
and other heart diseases; and experimental evidence of functional and structural 
changes in the myocardium in response to increased adiposity support the existence 
of a cardiomyopathy related to obesity.
Keywords: heart failure, obesity, adipokines, myocardiopathy
1. Introduction
During the past half-century, the advances in the prevention, diagnosis, and man-
agement of cardiovascular disease (CVD) have been spectacular. The cardiovascular- 
related deaths have declined by about two-thirds in industrialized nations [1].
Heart failure is characterized by an increased rate of cell death, which has been 
attributed to a variety of conditions: oxidative stress; abnormal elevations in circu-
lating neurohormones; toxins, such as alcohol or cancer chemotherapeutic drugs; 
excessive adrenergic activity; inflammation; and infiltrative processes. Apoptosis is a 
highly regulated type of cell death that normally increases with aging. It has been sug-
gested that, over time, the resulting deletion of myocytes leads to heart failure [2, 3].
The metabolic demand is increased in obesity; this is due to different factors 
as increasing blood volume, greater adipose tissue and lean mass, and as such, 
increased preload to the heart. In addition, in obese patients there are vascular 
alterations impacting arterial stiffness, and resistance increases afterload to the 
heart. In adults with obesity, both eccentric and concentric hypertrophies have been 
noted and are impacted by the duration and the degree of the obesity [4, 5].
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2. Regional adiposity and cardiovascular risk
While the cardiovascular risk is linked to the adipose tissue quantity, recent data 
indicate that differences in fat tissue quality, which can be examined directly by 
noninvasive computed tomography radiodensity attenuation imaging or by immu-
nohistochemistry, are closely linked to insulin resistance, cardiometabolic risk, 
and all-cause mortality, independent of total fat volume. These data demonstrate, 
independent of body mass index, that abnormalities at the adipose tissue level may 
be key factors that regulate systemic metabolism and drive cardiometabolic disease. 
These qualitative abnormalities in fat are a growing area of research interest that 
have been recently termed sick fat or adiposopathy and may in part explain the 
clinical observation of metabolically healthy obesity. The interindividual variability 
in adipose tissue “quality” may be related, in part, to differences in lifestyle, as 
physical activity has effects on adipose tissue physiology and cardiometabolic risk. 
While animal models of obesity tend to generate fairly uniform phenotypes, the 
degree of adipose tissue dysfunction in obese humans exhibits significant hetero-
geneity with lower degrees of adiposopathy being associated with more favorable 
systemic metabolic profiles and vascular function.
3. Adipokines, myokines, and cardiovascular disease
It is recognized that obesity contributes to cardiovascular and metabolic disor-
ders through alterations in the levels of adipocyte-derived cytokines that are named 
adipokines.
The functions of adipose tissue are as energy storage and as secretory tissue 
producing a variety of bioactive substances, including leptin, tumor necrosis factor 
alpha (TNFα), plasminogen activator inhibitor type 1, and adiponectin [6–9]. These 
bioactive molecules are generally referred to as adipokines, and several are involved 
in the pathophysiology of various obesity-linked disorders.
4. Leptin
Leptin is an adipose tissue-specific-secreted hormone and is highly expressed 
by adipocytes; this adipokine is encoded by the ob gene, which was identified in 
genetically obese ob/ob mice through positional cloning. The circulating leptin 
levels increase in parallel to adipose tissue mass. Leptin exerts important metabolic 
actions by suppressing appetite and increasing energy expenditure. Many lines of 
evidence suggest that hyperleptinemia contributes to cardiovascular complications. 
Leptin has pro-inflammatory actions in many immune cell types including mono-
cytes/macrophage, neutrophils, NK cells, and T cells [10–17].
5. Adiponectin
Adiponectin is abundantly present in human plasma at a range between 3 and 
30 μg/mL. It is an adipokine whose mRNA is largely expressed in adipose tissue. 
Adiponectin multimerizes to form stable higher-order complexes and shares struc-
tural homology with the collectin family of proteins.
Lower plasma levels of adiponectin are implicated in the pathogenesis of 
obesity-related diseases [18–21]. Conversely, plasma adiponectin concentrations 
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increase following weight loss [22, 23]. In patients with diabetes mellitus, the levels 
of adiponectin are lower than patients without diabetes matched for age and weight 
[14]. An inverse correlation has been demonstrated between circulating levels of 
adiponectin and those as C-reactive protein and interleukin 6 [24–27].
Adiponectin appears to protect against the development of various vascular 
diseases. In murine experiments, it has been demonstrated that adiponectin has an 
anti-atherogenic function. In apolipoprotein E-deficient mice, the administration 
of an adenovirus-expressing adiponectin reduces atherosclerotic lesion size [28]. 
In apolipoprotein E-deficient mice, the adiponectin deficit leads to an increase 
in vascular lesion area [29]. Adiponectin knockout mice also develop increased 
neointimal thickness and display increased vascular smooth muscle cell prolifera-
tion following acute arterial injury, whereas overexpression of adiponectin inhibits 
neointimal lesion formation in wild-type mice [30].
Experimental studies have found that adiponectin exerts beneficial actions 
on the heart under pathological conditions. Adiponectin-deficient mice develop 
severe cardiac hypertrophy, and there is increased mortality in response to pressure 
overload because of transverse aortic constriction [31, 32].
6. Interleukin 6
Interleukin 6 (IL-6) is known to be secreted by several tissues; it is a pleiotropic 
cytokine with complex roles in metabolic and cardiovascular disease. IL-6 also 
can act in a local fashion. However, adipose tissue is a major source of this protein, 
capable of producing high levels of this protein in the blood. It has been estimated 
that as much as one-third of total circulating IL-6 originates from adipose tissue. 
Therefore, IL-6 can be considered an adipokine with endocrine actions.
IL-6-induced cell signaling is typically classified as either classic or trans-
signaling, and it can lead to different cell responses. In the classic signaling way, the 
target cells are stimulated by IL-6 stimulates via a membrane-bound IL-6 receptor 
(IL6R), which upon ligand binding forms a complex with the signaling receptor 
protein gp130. Essentially all cells exhibit gp130 on the cell surface, whereas few cell 
types express membrane-bound IL6R. While the cells that only express gp130 are not 
responsive to IL-6 alone, they can be stimulated, via trans-signaling, by a complex of 
IL-6 bound to a naturally occurring soluble form of IL6R (sIL6R), markedly expand-
ing the spectrum of IL-6 actions and target cells.
7. Resistin
Resistin is highly expressed by mature adipocytes in rodents. This adipokine is 
a secreted protein that was initially suggested to be a major link between insulin 
resistance and obesity. Circulating resistin levels are increased in diabetic and obese 
mice, and the important role of resistin in metabolic dysfunction associated with 
obesity through pleiotropic effects on insulin sensitivity and glucose metabolism 
has been suggested in several loss- and gain-of-function studies in mice .
8. Myokines
Myokines have been defined as cytokines and proteins produced and released 
by myocytes under the action of contractile activity. They exert an autocrine, 
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paracrine, or endocrine effect. Their receptors were found in the muscle, fat, liver, 
pancreas, bone tissue, heart, brain, and immune cells [33, 34].
Although the endocrine function of adipose tissue has long been recognized, 
most of the factors produced are pro-inflammatory and harmful in the setting of 
obesity-induced metabolic disorders and cardiovascular disease. In this regard, 
adiponectin is relatively unique as an adipokine because it is expressed at highest 
levels in lean, healthy individuals.
Candidate cDNAs that encode secreted proteins and are differentially regulated 
in the muscle of the MyoMouse model are then used to construct adenoviral vectors 
for further testing in animal models of disease. One such factor, follistatin-like 1 
(Fstl1), was identified in this type of screen and shown to have cardiovascular- 
protective properties. Fstl1, also referred to as TSC36, is an extracellular glycopro-
tein that has been grouped into the follistatin family of proteins [35].
The main myokines studied to date are myostatin, decorin, irisin, myonectin, 
interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-15 (IL-15), follistatin, fibro-
blast growth factor 21 (FGF21), bone morphogenetic protein (BMP), and brain-
derived neurotrophic factor (BDNF). Other possible factors have been detected in 
the skeletal muscle, but their functions, as well as their presence in the circulation, 
are largely unknown: musclin and nonneuronal acetylcholine.
9. Myostatin
Also called growth differentiation factor 8 (GDF-8), it is a member of the 
transforming growth factor-β (TGF-β) family, expressed in developing and adult 
muscular tissue. It is one of the first described myokines.
Its main function is the negative regulation of the muscle mass, which means 
high level of myostatin and less muscle mass. It plays a role in stopping myoblast 
proliferation and suppressing satellite cell activation, inducing muscle atrophy. In 
addition, it influences the differentiation of muscle fibers by types (fast and slow) 
and the arrangement of muscle glucose as well as the muscle-adipose tissue cross-
talking [36–40].
10. Irisin
Discovered in 2012 as a transmembrane protein, FNDC5 has a cleaved soluble 
form, irisin, that it is released into circulation during the proteolytic process after 
acute exercising of skeletal muscles. It increases the energetic and oxidative metab-
olism of the muscle by activating genes related to these processes. It has a high level 
during myogenesis and induces glucose uptake improving glucose homeostasis, 
inhibiting lipid accumulation, and reducing body weight [41, 42]. Irisin has been 
studied especially in relation to obesity but also with myopathies such as muscular 
dystrophy. In these latter studies, injection of irisin induced muscle hypertrophy, 
improving muscle strength and reducing necrosis and development of connective 
tissue in a murine model [42].
11. Myonectin
Myonectin is a protein belonging to the C1q/TNF-related protein (CTRP) 
family, and it is found mainly in the muscle, less in circulation, being especially 
related to nutritional metabolism. Thus, the expression of myonectin is stimulated 
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by exercise and nutrients and is supposed to induce nutrient uptake and storage in 
other tissues, such as adipose tissue, causing a flux of glucose or fatty acids [42, 43].
12. Mechanism of myocardiopathy in obesity
Insulin resistance, adiposity, and adipokines have been implicated in the develop-
ment of abnormal myocardial mechanics in adults with obesity and type 2 diabetes. 
Adiposopathy in obese individuals is ultimately the consequence of a dysfunctional 
remodeling of the adipose tissue. Therefore, for understanding how obesity contrib-
utes to cardiovascular disease, it is primordial to know how both quantitative and 
qualitative effects of this adipose tissue remodeling contribute to that.
13. Adipose tissue expansion
In response to an excessive caloric intake, the mechanisms by which adipose 
depots expand represent an important determinant of the risk of cardiovascular 
disease and metabolic dysfunction. This expansion is mediated by two ways: an 
enlargement of adipocyte size (hypertrophy) and/or an increase in adipocyte 
numbers (hyperplasia).
Adipocyte hypertrophy typically leads to lipid-laden, dysfunctional adipocytes 
that undergo cell death and contribute to adipose tissue inflammation, dysfunction, 
and associated pathologies; in contrast it has been classically accepted that hyper-
plasia allows a “healthy” expansion of the adipose tissue, since it is mediated by the 
formation of functional adipocytes from progenitor cells (adipogenesis).
14. Immune cell infiltration
In most cases chronic excessive caloric intake eventually leads to adipocyte 
dysfunction, regardless of the mechanisms of adipose tissue expansion, and this 
is paralleled by qualitative and quantitative changes in the composition of adipose 
tissue at cellular level. Immune cells are of great relevance in this regard. Low-grade 
chronic inflammation is a major hallmark of adipose tissue in obesity, and it is 
now known that almost every immune cell type can be found in the adipose tis-
sue. Total numbers of B cells, T cells, neutrophils, macrophages, and mast cells are 
increased in visceral adipose tissue of obese individuals. In contrast, the number of 
eosinophils and specific subsets of T cells—T-helper type 2 (Th2) cells and regula-
tory T (Treg) cells—are decreased or remained static in the adipose tissue of obese 
individuals [36].
Macrophages are the most abundant immune cell in the adipose tissue of obese 
individuals, and their recruitment and proliferation upon high-calorie feeding is 
generally associated with adipose tissue inflammation and insulin resistance [44–47].
15. Impaired vascular structure and function
Several studies in humans and animal models have shown that obesity induces 
capillary rarefaction in adipose tissue, and this has been associated with metabolic 
dysfunction. It is widely a reduced adipose tissue; capillarization is present in 
obesity, and this reduced blood supply may limit nutrient delivery and contribute to 
adipocyte dysfunction and insulin resistance.
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Evidence of a causal role of adipose tissue vascularization in obesity-associated 
metabolic dysfunction have been shown in recent studies with genetically engi-
neered mice. Experiments demonstrated that an increased VEGF-mediated 
angiogenesis in adipose tissue can attenuate some of the metabolic effects of 
diet-induced obesity, such as insulin resistance and hepatic steatosis in mice overex-
pressing vascular endothelial growth factor A (VEGF-A) in adipocytes. Conversely, 
adipocyte-restricted deletion of VEGF-A results in diminished adipose tissue 
vascularization, which leads to increased adipose tissue inflammation and systemic 
metabolic dysfunction further supporting the noxious effects of reduced adipose 
tissue vascularity in obesity [48–51].
16. Adipose tissue fibrosis
Within the adipose tissue of lean organisms, adipocytes are surrounded by 
extracellular matrix that provides mechanical support and participates in cell 
signaling. There is a general increase in the synthesis of several extracellular matrix 
components with the development of obesity, in particular collagen VI, which leads 
to adipose tissue fibrosis and is associated with impaired metabolic function in 
mice. Adipose tissue fibrosis is increased in both subcutaneous and visceral depots 
in obesity. Obesity-induced adipose tissue fibrosis is due, at least in part, to hypoxia-
induced upregulation of hypoxia-inducible factor 1α (HIF1α). Interestingly, HIF1α 
activation does not contribute to an angiogenic response in this context, but instead 
promotes adipose tissue fibrosis [52].
17. Conclusions
An increasing evidence supports the evolving concept that quality, quantity, and 
location of adipose tissue are critical factors in shaping cardiometabolic pheno-
types in obese individuals. The specific pathogenic mechanisms and their relative 
contributions remain incompletely understood. Adipose tissue communicates with 
remote organs, including the heart and vasculature, through the release of various 
adipokines. While some adipokines have been highly studied and have shown to 
be causally linked to various disease processes, new adipokine candidates continue 
to be discovered and elucidated. In murine models and many human individuals, 
obesity leads to adipose tissue dysfunction; this dysfunction is termed adiposopa-
thy, particularly in visceral fat depots, which is mediated by dysfunctional tissue 
remodeling that involves adipocyte hypertrophy, increased fibrosis exacerbated 
inflammation, and impaired vascular function and structure. This ultimately cre-
ates a chronic, low-grade systemic inflammatory reaction mediated by an imbalance 
in adipokine levels which contributes to the initiation and progression of metabolic 
and cardiovascular complications. As our understanding of adipokines and obesity-
induced adiposopathy increases, the major challenge will reside in translating this 
information into new prognostic and therapeutic approaches to limit cardiovascular 
risk in obese individuals. Considering that a third of the world’s population is cur-
rently overweight or obese and this proportion is expected to increase in the coming 
decades, studies of adipokine biology should provide a better understanding of the 
pathogenesis of cardiovascular disease.
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